Myria Biosciences AG

Myria Biosciences is at the forefront of applying synthetic intelligence to transform drug development. The company's GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform combines synthetic biology and artificial intelligence into a synthetic intelligence approach that allows the design and biological production of therapeutic compounds far beyond what nature's evolution has provided. Myria is unlocking new chemical space and generating optimized molecular candidates with unprecedented speed and precision for unmet medical needs.